- On July 12, 2016, Zomedica announced the filing of a U.S. provisional application for patent with the U.S. Patent and Trademark Office and opened an INAD with the FDA-CVM for a novel formulation of ZM-006, a pharmaceutical targeting a metabolic disorder in companion animals.
- On August 25, 2016, Zomedica announced the closing of the first tranche of its non-brokered private placement offering, issuing 3,342,480 common shares for gross proceeds of approximately CDN$5,013,720 or $3,875,500.
- On September 19, 2016, Zomedica announced it was approved for graduation to Tier 1 issuer status from Tier 2 issuer status by the TSX Venture Exchange.
- On October 4, 2016, Zomedica announced the appointment of two animal health industry veterans, Jane Eagleson and Tom Robitaille, to its Board of Directors.
ANN ARBOR, Mich., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (TSX-V:ZOM) ("Zomedica" or "Company"), a veterinary pharmaceutical company, today reported condensed unaudited interim consolidated financial results for the three and nine months ended September 30, 2016. Amounts, unless specified otherwise, are expressed in U.S. dollars and are presented under International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS"). "We continue to build our unique companion animal health business," stated President and CEO Gerald Solensky Jr. "This quarter represents our first full quarter subsequent to the completion of our Qualifying Transaction resulting in our listing as a Life Sciences Issuer on the TSX Venture Exchange." Corporate Highlights